{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:01Z","timestamp":1787010181124,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,28]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Hemorrhagic cystitis can be a serious side effect of some chemotherapy drugs like cyclophosphamide and ifosfamide. Docetaxel is a taxane that is used to treat several malignancies including breast and prostate cancer. Hemorrhagic cystitis has not been described as a complication of combination chemotherapy with docetaxel, particularly docetaxel with carboplatin, trastuzumab and pertuzumab (TCHP) in breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>Both patients had a history of locally advanced human epidermal growth factor receptor 2 positive breast cancer and complaint of hematuria after their first treatment with TCHP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>They were diagnosed with hemorrhagic cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Docetaxel was discontinued and changed to paclitaxel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Both patients completed neoadjuvant chemotherapy and did not have further episodes of hemorrhagic cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Hemorrhagic cystitis is a rare complication of combination chemotherapy with docetaxel (TCHP). Clinicians should be vigilant for signs and symptoms of hemorrhagic cystitis in patients receiving docetaxel and alternative treatment option should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000041906","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:46:28Z","timestamp":1743356788000},"page":"e41906","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling the Crimson puzzle: Two case reports\/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer"],"prefix":"10.1097","volume":"104","author":[{"given":"Juan C.","family":"Ramirez","sequence":"first","affiliation":[{"name":"Department of Medical Education, Florida International University Herbert Wertheim College of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel E.","family":"Lacey","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Florida International University Herbert Wertheim College of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya S.","family":"Gowda","sequence":"additional","affiliation":[{"name":"College of Agriculture and Life Sciences, Cornell University, Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Baptist Health South Florida, Miami Cancer Institute, Miami, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-2960","authenticated-orcid":false,"given":"Yolcar","family":"Chamorro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Baptist Health South Florida, Miami Cancer Institute, Miami, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Sandoval-Leon","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Florida International University Herbert Wertheim College of Medicine, Miami, FL"},{"name":"Department of Medical Oncology, Baptist Health South Florida, Miami Cancer Institute, Miami, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/00099228231175473","article-title":"Hemorrhagic cystitis due to cephalexin and review of the literature.","volume":"63","author":"Gan","year":"2024","journal-title":"Clin Pediatr (Phila)"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0970-1591.65380","article-title":"Hemorrhagic cystitis: a challenge to the urologist.","volume":"26","author":"Manikandan","year":"2010","journal-title":"Indian J Urol"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"27","DOI":"10.28920\/dhm52.1.27-34","article-title":"Hyperbaric oxygen treatment for refractory haemorrhagic cystitis occurring after chemotherapy and haematopoietic stem cell transplantation: retrospective analysis of 25 patients.","volume":"52","author":"Ozturk","year":"2022","journal-title":"Diving Hyperb Med"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-006-0078-0","article-title":"Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.","volume":"23","author":"Korkmaz","year":"2007","journal-title":"Cell Biol Toxicol"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/CMO.S4477","article-title":"Hemorrhagic cystitis in a patient receiving docetaxel for prostate cancer.","volume":"4","author":"Ntekim","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"220","DOI":"10.18632\/oncoscience.444","article-title":"Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis.","volume":"5","author":"Du","year":"2018","journal-title":"Oncoscience"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CMAR.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer.","volume":"6","author":"Ho","year":"2014","journal-title":"Cancer Manag Res"},{"key":"R9-20250328","article-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 5.2024.","year":"2024"},{"key":"R10-20250328","article-title":"Highlight of Prescribing information: Neulasta.","year":"2019"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:46:44Z","timestamp":1743356804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":9,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041906","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}